Educational Symposium
Acute Kidney Dysfunction in Cirrhosis: A Case-Based Conversation about Diagnosis and Treatment
October 26, 2024 | 12:45 PM - 01:45 PM
Location: Marriott Grand Ballroom 5, Marriott Marquis
Session Description
AKI is prevalent among individuals with cirrhosis and is associated with an unfavorable prognosis. Hepatorenal syndrome type 1, now referred to as HRS-AKI, is one of the patterns of acute kidney dysfunction observed in patients with cirrhosis, but not the only pattern. For the subset who develop HRS-AKI, the median survival time is approximately two weeks, with over 80% mortality within three months. Numerous interventions for patients with kidney dysfunction in cirrhosis have been studied, including the use of volume expansion with albumin and vasoconstriction with midodrine, octreotide, norepinephrine, and, more recently, terlipressin. Differentiating HRS-AKI from other etiologies of kidney dysfunction and navigating the various therapeutic options is a challenge for clinicians caring for patients with cirrhosis.In this symposium, clinical cases are used to explain the pathophysiology of various patterns of kidney dysfunction in patients with cirrhosis and propose evidence-based strategies for treatment.
Support is provided by an educational grant from Mallinckrodt Pharmaceuticals.
Learning Objective(s)
- Characterize the pathophysiology of HRS-AKI
- Differentiate HRS-AKI from kidney dysfunction from other causes in cirrhosis
- Select the optimal management strategy for a patient with kidney dysfunction in the context of cirrhosis
Learning Pathway(s)
- AKI and Critical Care
- Pharmacology
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- The Differential Dance: A Case-Based Discussion of Etiologies and Mechanisms of Acute Kidney Dysfunction in Cirrhosis
12:55 PM - 01:15 PM
- Mastering Management: A Case-Based Discussion of Therapies for Acute Kidney Dysfunction in Cirrhosis
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM